Skip to content

Widespread Cortical Thickness Reductions Following Non-medical Use of Ketamine: a Structural MRI Study of Individuals with Ketamine Dependence

Jinsong Tang, Qiuxia Wu, Chang Qi, An Xie, Jianbin Liu, Yunkai Sun, Tifei Yuan, Wei Chen, Tieqiao Liu, Wei Hao, Yanhui Liao

medRxiv Preprint Server February 21, 2021 preprint DOI: 10.1101/2021.02.21.21252178 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Observational cohort
Population Chronic ketamine users
Intervention ketamine
Topics Addiction Esketamine Ketamine
Keywords Ketamine abuse Recreational ketamine use Illicit ketamine Ketamine dependence Drug abuse Brain changes Cortical thinning Neurological impact Brain structure Neurotoxicity Brain health Neuroimaging MRI Scans Brain imaging Medical imaging
Key findings Chronic, non-medical ketamine use is associated with cortical thickness abnormalities in the brain.

Abstract

Background A version of ketamine, called Esketamine has been approved for treatment-resistant depression (TRD). Ketamine (“K powder”), a “dissociative” anesthetic agent, however, has been used non-medically alone or with other illicit substances. Our previous studies showed a link between non-medical ketamine use and brain structural and functional alterations. We found dorsal prefrontal gray matter reduction in chronic ketamine users. It is unknown, however, whether these observations might parallel findings of cortical thickness alterations. This study aimed at exploring cortical thickness abnormalities following non-medical, long-term use of ketamine.

Comparable studies

Other observational and cohort studies on ketamine for addiction, most cited first.

Study Year Design Participants
Brain damages in ketamine addicts as revealed by magnetic resonance imaging Ketamine addicts 2014 Observational cohort n = 21
Characterization of Oral Ketamine Use: A Retrospective Review. Hospitalized patients aged 18 years or older receiving oral ketamine 2025 Retrospective cohort study
Maintenance Intramuscular Ketamine-Assisted Psychotherapy, a Retrospective Chart Review of Efficacy, Adverse Events, and Dropouts from a Community Practice. Patients receiving intramuscular ketamine with contemporaneous psychotherapy for... 2024 Observational study n = 70
Prescribing bias and adverse outcomes of esketamine in major depression comorbid substance. Adults aged 18 years or older with major depressive disorder in the TriNetX US... 2026 Retrospective cohort study n = 30,670
Ketamine Therapy for Chronic Pain Provides Added Benefits for Substance Misuse Therapy Adult chronic pain patients with comorbid substance misuse 2026 Observational study n = 20

Explore topics

By condition and practice